Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy

Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy

Abstract Introduction Alzheimer’s disease is a neurocognitive disorder that affects elderly people by slowly impaired cognition, dementia, and gets worse with age. It slowly impacts the quality of life. Clinically, it is distinguished by a transition from episodic memory to a gradual reduction in co...

Full description

Bibliographic Details
Main Authors:	Devika Jadhav, Nikita Saraswat, Neeraj Vyawahare, Devendra Shirode
Format:	Article
Language:	English
Published:	SpringerOpen 2024-01-01
Series:	The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Subjects:	Aducanumab Alzheimer’s disease β-Amyloid Cholinesterase inhibitors Dementia Cognitive dysfunction
Online Access:	https://doi.org/10.1186/s41983-023-00775-8

Similar Items

Neurodegenerative diseases: from gut-brain axis to brain microbiome
by: Robert P. Friedland, et al.
Published: (2023-05-01)

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
by: Rouen Brockmann, et al.
Published: (2023-04-01)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders
by: Giovanni B Frisoni, et al.
Published: (2021-08-01)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01)

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
by: Wenxue Wu, et al.
Published: (2023-11-01)

Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease
by: Jakub Wojcieszak
Published: (2023-05-01)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
by: Karolina Wojtunik-Kulesza, et al.
Published: (2023-02-01)

Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease
by: Jürgen Götz, et al.
Published: (2021-07-01)

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease
by: Md. Sahab Uddin, et al.
Published: (2020-08-01)

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
by: Dominik Glinz, et al.
Published: (2019-06-01)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
by: George P. Paraskevas, et al.
Published: (2021-09-01)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
by: Martin Tolar, et al.
Published: (2021-06-01)

Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01)

Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection
by: Shoaib Shoaib, et al.
Published: (2023-02-01)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy
by: Houman Sotoudeh, et al.
Published: (2024-01-01)

Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
by: Denisa Claudia Miculas, et al.
Published: (2022-12-01)

Dementia patients have greater anti-cholinergic drug burden on discharge from hospital: A multicentre cross-sectional study
by: J. Randall, et al.
Published: (2021-04-01)

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data
by: Minjae Kang, et al.
Published: (2022-08-01)

Alzheimer’s disease: A Threat to mankind
by: Poorti Pandey, et al.
Published: (2011-12-01)

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
by: Leo Bon, et al.
Published: (2024-02-01)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
by: Serena Silvestro, et al.
Published: (2022-02-01)

Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report
by: Houman Sotoudeh, MD, et al.
Published: (2023-01-01)

Development of Bioactive Molecules for the Treatment of Alzheimer’s Disease
by: Amisha Punmiya, et al.
Published: (2022-11-01)

Preventive Role of Indian Black Pepper in Animal Models of Alzheimer’s Disease
by: Lokraj Subedee, et al.
Published: (2015-04-01)

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
by: Vahit Yigit, et al.
Published: (2023-08-01)

Effects of Linkers and Substitutions on Multitarget Directed Ligands for Alzheimer’s Diseases: Emerging Paradigms and Strategies
by: Narayanaperumal Pravin, et al.
Published: (2022-05-01)

Aducanumab: an uprising hope with vague horizons
by: Delara Hazegh Fetratjoo, et al.
Published: (2023-06-01)

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
by: Hafsa Amat-ur-Rasool, et al.
Published: (2021-02-01)

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
by: Sam Gandy
Published: (2023-09-01)

Regular proton pump inhibitor use and incident dementia: population-based cohort study
by: Peidong Zhang, et al.
Published: (2022-09-01)

Dementia post-radiotherapy: improvement with acetylcholinesterase inhibitor A case report
by: Antonio Eduardo Damin, et al.

Biomarkers of Alzheimer’s disease: Past, present and future clinical use
by: Joanna E. Georgakas, et al.
Published: (2023-06-01)

Development of monoclonal antibody therapeutics for alzheimer's disease
by: Masatoshi Takeda
Published: (2022-01-01)

The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)

Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics
by: Shiveena Bhatia, et al.
Published: (2023-08-01)

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
by: Chanho Kong, et al.
Published: (2022-12-01)

The therapeutic value of thiazole and thiazolidine derivatives in Alzheimer's disease: a systematic literature review
by: Zahra Abdollahi, et al.
Published: (2024-01-01)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
by: Yi-Ting Lin, et al.
Published: (2019-05-01)

A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE)
by: Tereza Cristina Santos Evangelista, et al.
Published: (2022-12-01)

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
by: Matthias Pawlowski, et al.
Published: (2017-07-01)